AstraZeneca sees profits surge despite Chinese import tax allegations

[
Profit after tax rose to $7 billion last year, up from $6 billion in 2023, the company said, noting a sharp increase in sales of cancer medicines. Read More
https://fortune.com/img-assets/wp-content/uploads/2025/02/GettyImages-1247540867-e1738838327829.jpg?resize=1200,600
https://fortune.com/europe/2025/02/06/astrazeneca-profits-surge-chinese-import-tax-allegations/


AFP